Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- The colonoscopy reimbursement math is not adding up (Becker’s Healthcare)
- Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey (Fierce Healthcare)
- Microbiome Testing Needs Its Standards Moment (Op-Med)
- Combined GI Endoscopy Has a Quality Assurance Gap. At Current Volume, That Gap Has Institutional Consequences. (HIT Consultant)
- Computer-aided polyp detection multicenter international randomized controlled study with a focus on community clinics: Gastroenterology Artificial INtelligence system for detecting colorectal polyps (ScienceDirect)
- Researchers Analyzing Colon Cancer Screenings Find Hope for Higher Retest Rates (Rutgers)
- Exclusive: Co-Founded By Former Whoop CTO, Throne Science Raises $10M To Track Gut Health From The Toilet (Crunchbase)
- GI Societies Oppose Proposed Federal Rule That Would Reshape Biomedical Research (American College of Gastroenterology)
